Current issues in the management of paediatric viral hepatitis

Liver International

Volumn 30, Issue 1, 2010, Pages 5-18

  Yeung, Latifa T F ^a,b,c   Roberts, Eve A ^b,c,d  

^a Rouge Valley Health System   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute liver failure; Child; Cirrhosis; Eseroconversion; Fibrosis; Hepatitis; Hepatocellular carcinoma; Pegylated interferon ; Post exposure prophylaxis; Ribavirin; Treatment; Vaccine; Vertical transmission; Virus

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; HEPATITIS E VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; PLACEBO; PREDNISONE; RIBAVIRIN; STEROID; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; VIVAXIM;

ALOPECIA; ANOREXIA; ANTIVIRAL THERAPY; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GENETIC VARIABILITY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; INFECTION PREVENTION; INSULIN RESISTANCE; LEUKOPENIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MALAISE; MYALGIA; NAUSEA; OBESITY; POLYMERASE CHAIN REACTION; REVIEW; RISK BENEFIT ANALYSIS; SEROCONVERSION; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS DIAGNOSIS; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION; VOMITING;

ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS E; HEPATITIS E VIRUS; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON ALFA-2A; LIVER FAILURE, ACUTE; POLYETHYLENE GLYCOLS; PREGNANCY; RIBAVIRIN; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 73449085495     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02145.x     Document Type: Review

References (106)

1. Salama II, Samy SM, Shaaban FA, Hassanin AI, Abou Ismail L.A. Seroprevalence of hepatitis A among children of different socioeconomic status in Cairo. East Mediterr Health J 2007; 13: 1256-64.
2. Ciocca M, Moreira-Silva SF, Alegria S, et al. Hepatitis A as an etiologic agent of acute liver failure in Latin America. Pediatr Infect Dis J 2007; 26: 711-5.
3. Chen YC, Huang LT, Wang SM, Tiao MM, Liu J.W. Acute hepatitis A infection in children: a 20-year experience of a medical center in Southern Taiwan. Acta Paediatr Taiwan 2007; 48: 131-4.
4. Ciocca M, Ramonet M, Cuarterolo M, et al. Prognostic factors in paediatric acute liver failure. Arch Dis Child 2008; 93: 48-51.
5. Ellis A, Ruttimann RW, Jacobs RJ,Meyerhoff AS, Innis B.L. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev Panam Salud Publica 2007; 21: 345-56.
6. Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 2007; 42: 152-60.
7. Aydogdu S, Ozgenc F, Yurtsever S, et al. Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J Trop Pediatr 2003; 49: 367-70.
8. Mathur P, Arora N.K. Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries. Indian J Med Res 2008; 128: 699-704.
9. Arora NK, Nanda SK, Gulati S, et al. Acute viral hepatitis types E, A, and B singly and in combination in acute liver failure in children in north India. J Med Virol 1996; 48: 215-21.
10. Samanta T, Ganguly S. Aetiology, clinical profile and prognostic indicators for children with acute liver failure admitted in a teaching hospital in Kolkata. Trop Gastroenterol 2007; 28: 135-9.
11. Bhowmick K, Mammen A, Moses PD, et al. Hepatitis A in pediatric acute liver failure in southern India. Indian J Gastroenterol 2005; 24: 34.
12. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis - United States, 2006. MMWR Surveill Summ 2008; 57: 1-24.
13. Williams I, Wasley A, Darling N, Singleton J, Fischer G. Hepatitis A vaccination coverage among children aged 24-35 months - United States, 2004-2005. Morb Mortal Wkly Rep 2007; 56: 678-81.
14. American Academy of Pediatrics: Committee on Infectious Diseases. Hepatitis A vaccine recommendations. Pediatrics 2007; 120: 189-99.
15. Blaine Hollinger F, Bell B, Levy-Bruhl D, et al. Hepatitis A and B vaccination and public health. J Viral Hepat 2007; 14(Suppl. 1): 1-5.
16. Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med Infect Dis 2007; 5: 171-5.
17. Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Longterm antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 2008; 26: 1759-63.
18. Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007; 357: 1685-94.
19. Baker C.J. Another success for hepatitis A vaccine. N Engl J Med 2007; 357: 1757-9.
20. Bauch CT, Rao AS, Pham BZ, et al. A dynamic model for assessing universal hepatitis A vaccination in Canada. Vaccine 2007; 25: 1719-26.
21. Chang M.H. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 2009; 181: 85-94.
22. Omenaca F, Garcia-Sicilia J, Boceta R, Sistiaga-Hernando A, Garcia-Corbeira P. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007; 26: 824-9.
23. Stojanov S, Liese JG, Belohradsky BH, et al. Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine. Vaccine 2007; 25: 7549-58.
24. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25: 6958-64.
25. Su FH, Cheng SH, Li CY, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085-90.
26. Pielak KL, McIntyre CC, Remple VP, Buxton JA, Skowronski D.M. One arm or two? Concurrent administration of meningococcal C conjugate and hepatitis B vaccines in pre-teens. Can J Public Health 2008; 99: 52-6.
27. Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 2007; 161: 1176-82.
28. Velu V, Saravanan S, Nandakumar S, et al. Transmission of "a" determinant variants of hepatitis B virus in immunized babies born to HBsAg carrier mothers. Jpn J Infect Dis 2008; 61: 73-6.
29. Ijaz S, Khulan J, Bissett SL, et al. A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia. J Med Virol 2006; 78: 1554-9.
30. Mu SC, Lin YM, Jow GM, Chen B.F. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol 2009; 50: 264-72.
31. Sheldon J, Ramos B, Garcia-Samaniego J, et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007; 46: 279-82.
32. Liu CJ, Kao JH, Chen D.S. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005; 25: 1097-107.
33. Wu TC, Tong MJ, Hwang B, Lee SD, Hu M.M. Primary hepatocellular carcinoma and hepatitis B infection during childhood. Hepatology 1987; 7: 46-8.
34. Fujisawa T, Komatsu H, Inui A, et al. Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J Pediatr Gastroenterol Nutr 2000; 30: 201-6.
35. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-62.
36. Sagnelli E, Stroffolini T,Mele A, Imparato M, Almasio P.L. Chronic hepatitis B in Italy: new features of an old disease - approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis 2008; 46: 110-3.
37. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
38. Lok AS, McMahon B.J. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
39. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
40. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
41. Mendy ME, McConkey SJ, Sande van der MA, et al. Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in the Gambia. J Virol 2008; 5: 49.
42. Lai CL, Yuen M.F. The natural history of chronic hepatitis B. J Viral Hepat 2007; 14(Suppl. 1): 6-10.
43. Lin ZQ, Fang F, Guo ZF, Chen Q. Effect of interferonalpha treatment in children with hepatitis B e antigenpositive chronic hepatitis B virus infection: a metaanalysis of follow-up for six months to two years. Zhonghua Er Ke Za Zhi 2007; 45: 592-8.
44. Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-13.
45. Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir diprivoxil in children and adolescents (age 2 to o18 years) with chronic hepatitis B. Hepatology 2008; 47: 1863-71.
46. Jonas MM, Little NR, Gardner S.D. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hep 2008; 15: 20-7.
47. Lai CL, Lin HJ, Lau JN, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991; 78: 155-63.
48. Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23: 700-7.
49. Boxall EH, Sira J, Ballard AL, Davies P, Kelly D.A. Longterm follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol 2006; 78: 888-95.
50. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745-54.
51. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-54.
52. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
53. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
54. Lai CL, Yuen M.F. Chronic hepatitis B - new goals, new treatment. N Engl J Med 2008; 359: 2488-91.
55. Bortolotti F, Jara P, Barbera C, et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-8.
56. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002; 186: 295-301.
57. Hsu HY, Tsai HY, Wu TC, et al. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int 2008; 28: 1288-97.
58. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosisrelated complications. Hepatology 2001; 34: 139-45.
59. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9.
60. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
61. Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996; 23: 131-7.
62. Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998; 61: 219-23.
63. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol R.J. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr 1995; 127: 815-8.
64. Burczynska B, Madalinski K, Pawlowska J, et al. The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children. J Hepatol 1994; 21: 1097-102.
65. D'Antiga L, Aw M, Atkins M, et al. Combined lamivudine/ interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006; 148: 228-233.
66. Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007; 5: 636-41.
67. Iorio R, Giannattasio A, Cirillo F, D'Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007; 45: 943-9.
68. Zacharakis G, Koskinas J, Kotsiou S, et al. Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years' follow-up in northern Greece. J Pediatr Gastroenterol Nutr 2007; 44: 84-91.
69. Soderstrom A, Lindh M, Ekholm K, et al. Predictive factors and virological response to interferon treatment in children with chronic hepatitis B. Scand J Infect Dis 2005; 37: 40-7.
70. Ozen H, Kocak N, Gurakan F, Yuce A. Recombinant interferon-alpha-2A with or without steroid pretreatment in children with chronic hepatitis B. Turk J Pediatr 1998; 40: 503-14.
71. Kim HS, Kim JW, Chung K.S. Treatment of chronic hepatitis B in children with prednisolone withdrawal followed by recombinant interferon alpha. Yonsei Med J 1998; 39: 309-16.
72. Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996; 15: 223-31.
73. Gomez Camacho F, Poyato Gonzalez A, Vignote Alguacil ML, et al. Comparison of 2 treatment strategies with prednisone and interferon in chronic hepatitis B. Rev Esp Enferm Dig 1996; 88: 185-90.
74. Giacchino R, Main J, Timitilli A, et al. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995; 15: 143-8.
75. Utili R, Sagnelli E, Gaeta GB, et al. Treatment of chronic hepatitis B in children with prednisone followed by alfainterferon: a controlled randomized study. J Hepatol 1994; 20: 163-7.
76. Mellerup MT, Krogsgaard K, Mathurin P, Gluud C, Poynard T. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database Syst Rev 2002:CD000345.
77. Barlow CF, Priebe CJ,Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132: 527-30.
78. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr 1999; 135: 782-5.
79. Chu CM, Liaw Y.F. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepatol 2007; 14: 147-52.
80. Yeung L, King S, Roberts E. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-9.
81. Canadian Association for the Study of the Liver Consensus Conference Rapporteur Group. Canadian Consensus Conference on the Management of Viral Hepatitis. Can J Gastroenterol 2000; 14: 5B-20B.
82. American Academy of Pediatrics: Committee on Infectious Diseases. Hepatitis C virus infection. Pediatrics 1998; 101: 481-5.
83. Veronesi L, Verrotti Di Pianella C, Benassi L, et al. Mother to child transmission of hepatitis C virus in a province of northern Italy. J Prev Med Hyg 2007; 48: 47-9.
84. Marine-Barjoan E, Berrebi A, Giordanengo V, et al. HCV/ HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS 2007; 21: 1811-5.
85. England K, Pembrey L, Tovo PA, Newell M.L. Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. Acta Paediatr 2005; 94: 444-50.
86. Polywka S, Pembrey L, Tovo PA, Newell M.L. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78: 305-10.
87. Yeung LT, To T, King SM, Roberts E.A. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepatol 2007; 14: 797-805.
88. Simanis R, Lejniece S, Sochnevs A, et al. Natural clearance of hepatitis C virus in hemophilia patients. Medicina 2008; 44: 15-21.
89. El-Hawary MA, El-Raziky MS, Esmat G, et al. Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol 2007; 13: 2846-51.
90. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47: 836-43.
91. Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900-7.
92. Kao JT, Wang JH, Hung CH, et al. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. Liver Int 2008; 28: 1298-304.
93. Liakina V, Speiciene D, Irnius A, Semuchiniene T, Valantinas J. Association of the prevalence and grade of steatosis in patients with chronic hepatitis C with the host and viral factors. Acta Gastroenterol 2007; 70: 260-6.
94. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 723-31.
95. Harris HE, Mieli-Vergani G, Kelly D, et al. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 2007; 45: 335-41.
96. Jara P, Hierro L, de la Vega A, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142-8.
97. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Sluzewski W. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiol Drug Saf 2007; 16: 1095-103.
98. Schwarz KB, Gonzalez-Peralta PR, Murray KF, et al. PEGinterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the PEDS-C trial. Hepatology 2008; 48: 418A.
99. Murray KF, Rodrigue JR, Gonzalez-Peralta RP, et al. Design of the PEDS-C trial: pegylated interferon+/( ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007; 4: 661-73.
100. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-8.
101. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
102. Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune suppression leading to hepatitis C virus reemergence after sustained virological response. J Med Virol 2008; 80: 1720-2.
103. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356: 895-903.
104. Zhang J, Liu CB, Li RC, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009; 27: 1869-74.
105. Tacke F, Trautwein C. Efficient recombinant hepatitis E virus vaccine: mission accomplished? Hepatology 2007; 46: 941-3.
106. Krawczynski K. Hepatitis E vaccine - ready for prime time? N Engl J Med 2007; 356: 949-51.